Targeting tubular NAT10 ameliorates the renal Tubulointerstitial Fibrosis in Obstructive and Folic Acid-Induced Nephropathy

Qin Kang, Lin Yin, Chenkai Wu, Wende Yan, Sai Peng, Jinfang Lu, Dongshan Zhang · 2026

Read Targeting tubular NAT10 ameliorates the renal Tubulointerstitial Fibrosis in Obstructive and Folic Acid-Induced Nephropathy by Qin Kang, Lin Yin, Chenkai Wu, Wende Yan, Sai Peng, Jinfang Lu, Dongshan Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13618001.txt.

Description

Qin Kang and co-authors identify an enzyme that drives scarring in the kidney and show that blocking it helps in mice. The scarring process, tubulointerstitial fibrosis, is the shared end path of chronic kidney disease. The enzyme NAT10 chemically marks RNA messages. A master growth signal raises NAT10 levels through the p53 pathway in kidney tubule cells.

NAT10 steadies the message for a second protein, Spred2, which then switches on two signaling routes that feed the scarring program. Mice bred to lack NAT10 only in tubule cells developed far less scarring in two different kidney injury models. A drug called 5-fluorouridine, which targets NAT10, likewise eased scarring in both models. The authors name a full chain from p53 through NAT10 and Spred2 to the scarring signals. They propose the drug as a candidate treatment for kidney fibrosis.

Catalog record

CREATORQin Kang, Lin Yin, Chenkai Wu, Wende Yan, Sai Peng, Jinfang Lu, Dongshan Zhang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13618001

Browse the full library · About the Tower of Babel